FY2025 · ended Dec 31, 2025 · Revenue $20.18M, +4.2% YoY · Filed Mar 11, 2026
Evofem Biosciences, Inc. (EVFM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $20.2 million and net income of $391,000. Free cash flow was -$2.0 million. As of Jun 30, 2026 it held $285,000 in cash and investments and $480,000 in total debt.
Revenue (TTM)
$18.05M
+4.5% vs year-ago TTM
Net income (TTM)
$-15.28M
-145.3% vs year-ago TTM
Operating cash flow (TTM)
$-472,000
+91.0% vs year-ago TTM
Free cash flow (TTM)
$-477,000
+90.9% vs year-ago TTM
EPS (TTM)
$-0.00
+95.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
132.53M
+16.9% vs prior year
Net cash
$-195,000
as of Jun 30, 2026
Operating margin
-15.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EVFM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1618835
- Former names
- Neothetics, Inc. (until Jan 5, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $20.2M | $19.4M | $18.2M | $16.8M | $8.2M |
| Operating income | $3.4M | -$7.7M | -$17.8M | -$84.1M | -$166.8M |
| Net income | $391,000 | -$8.9M | $53.0M | -$76.7M | -$205.2M |
| Diluted EPS | $0.00 | -$0.11 | $0.05 | -$167.42 | -$23.63 |
| Operating cash flow | -$2.0M | -$3.9M | -$9.0M | -$70.4M | -$146.7M |
| Free cash flow | -$2.0M | -$3.9M | -$9.0M | -$70.8M | -$149.6M |
| Total assets | $20.3M | $23.8M | $10.6M | $25.2M | $42.5M |
| Total liabilities | $89.7M | $90.3M | $72.5M | $97.0M | $142.1M |
| Stockholders' equity | -$74.3M | -$71.3M | -$66.5M | -$71.8M | -$104.3M |
| Cash and investments | $578,000 | — | — | $2.8M | $7.7M |
| Total debt | $329,000 | $224,000 | $100,000 | $5.4M | $6.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 15, 2026 | Oct 9, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 14, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Results of operations
|
May 18, 2026 | May 18, 2026 |
All 802 Evofem Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.